カテゴリー： Market Monitor Global, 世界, 医療/バイオ

肺動脈高血圧症治療の世界市場見通し2023年-2029年

◆英語タイトル：Pulmonary Arterial Hypertension Treatment Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8618 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月 ◆ページ数：66 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Pulmonary Arterial Hypertension Treatment Market 調査レポートは次の情報を含め、グローバルにおけるの肺動脈高血圧症治療市場規模と予測を収録しています。・世界の肺動脈高血圧症治療市場：売上、2018年-2023年、2024年-2029年
・世界の肺動脈高血圧症治療市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の肺動脈高血圧症治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「血管拡張薬」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

肺動脈高血圧症治療のグローバル主要企業は、GSK、 Eli Lilly and Company、 Pfizer Inc、 Actelion Inc、 United Therapeutic Corporation、 SteadyMed Ltd、 Gilead Sciences, Inc、 Teva Pharmaceuticals Inc、 Bayer AGなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、肺動脈高血圧症治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の肺動脈高血圧症治療市場：タイプ別、2018年-2023年、2024年-2029年
世界の肺動脈高血圧症治療市場：タイプ別市場シェア、2022年
・血管拡張薬、ホスホジエステラーゼ5（PDE 5）阻害薬、エンドセリン受容体拮抗薬（ERA）、可溶性グアニル酸シクラーゼ（SGC）刺激薬

世界の肺動脈高血圧症治療市場：用途別、2018年-2023年、2024年-2029年
世界の肺動脈高血圧症治療市場：用途別市場シェア、2022年
・病院薬局、小売薬局、オンライン薬局

世界の肺動脈高血圧症治療市場：地域・国別、2018年-2023年、2024年-2029年
世界の肺動脈高血圧症治療市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における肺動脈高血圧症治療のグローバル売上、2018年-2023年
・主要企業における肺動脈高血圧症治療のグローバル売上シェア、2022年
・主要企業における肺動脈高血圧症治療のグローバル販売量、2018年-2023年
・主要企業における肺動脈高血圧症治療のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
GSK、 Eli Lilly and Company、 Pfizer Inc、 Actelion Inc、 United Therapeutic Corporation、 SteadyMed Ltd、 Gilead Sciences, Inc、 Teva Pharmaceuticals Inc、 Bayer AG

*************************************************************

・調査・分析レポートの概要
肺動脈高血圧症治療市場の定義
市場セグメント
世界の肺動脈高血圧症治療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の肺動脈高血圧症治療市場規模
世界の肺動脈高血圧症治療市場規模：2022年 VS 2029年
世界の肺動脈高血圧症治療市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの肺動脈高血圧症治療の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の肺動脈高血圧症治療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：血管拡張薬、ホスホジエステラーゼ5（PDE 5）阻害薬、エンドセリン受容体拮抗薬（ERA）、可溶性グアニル酸シクラーゼ（SGC）刺激薬
肺動脈高血圧症治療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院薬局、小売薬局、オンライン薬局
肺動脈高血圧症治療の用途別グローバル売上・予測

・地域別市場分析
地域別肺動脈高血圧症治療市場規模 2022年と2029年
地域別肺動脈高血圧症治療売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
GSK、 Eli Lilly and Company、 Pfizer Inc、 Actelion Inc、 United Therapeutic Corporation、 SteadyMed Ltd、 Gilead Sciences, Inc、 Teva Pharmaceuticals Inc、 Bayer AG
...

Pulmonary arterial hypertension- commonly known as PAH- is characterized by increased pressure in the pulmonary arteries due to structural changes in blood vessel walls, aggregation of platelets and alteration of smooth muscle cell function- eventually elevating pressure in the pulmonary arteries responsible for pumping blood to the lungs. This eventually leads to right heart failure and, ultimately, death.
This report aims to provide a comprehensive presentation of the global market for Pulmonary Arterial Hypertension Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Arterial Hypertension Treatment. This report contains market size and forecasts of Pulmonary Arterial Hypertension Treatment in global, including the following market information:
Global Pulmonary Arterial Hypertension Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Pulmonary Arterial Hypertension Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Vasodilators Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Pulmonary Arterial Hypertension Treatment include GSK, Eli Lilly and Company, Pfizer Inc, Actelion Inc, United Therapeutic Corporation, SteadyMed Ltd, Gilead Sciences, Inc, Teva Pharmaceuticals Inc and Bayer AG, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Pulmonary Arterial Hypertension Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Pulmonary Arterial Hypertension Treatment Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Pulmonary Arterial Hypertension Treatment Market Segment Percentages, by Type, 2022 (%)
Vasodilators
Phosphodiesterase 5 (PDE 5) Inhibitors
Endothelin Receptor Antagonists (ERA)
Soluble Guanylate Cyclase (SGC) Stimulator
Global Pulmonary Arterial Hypertension Treatment Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Pulmonary Arterial Hypertension Treatment Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Pulmonary Arterial Hypertension Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Pulmonary Arterial Hypertension Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Pulmonary Arterial Hypertension Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Pulmonary Arterial Hypertension Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
GSK
Eli Lilly and Company
Pfizer Inc
Actelion Inc
United Therapeutic Corporation
SteadyMed Ltd
Gilead Sciences, Inc
Teva Pharmaceuticals Inc
Bayer AG
Outline of Major Chapters:
Chapter 1: Introduces the definition of Pulmonary Arterial Hypertension Treatment, market overview.
Chapter 2: Global Pulmonary Arterial Hypertension Treatment market size in revenue.
Chapter 3: Detailed analysis of Pulmonary Arterial Hypertension Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Pulmonary Arterial Hypertension Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Pulmonary Arterial Hypertension Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Pulmonary Arterial Hypertension Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Pulmonary Arterial Hypertension Treatment Overall Market Size
2.1 Global Pulmonary Arterial Hypertension Treatment Market Size: 2022 VS 2029
2.2 Global Pulmonary Arterial Hypertension Treatment Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Pulmonary Arterial Hypertension Treatment Players in Global Market
3.2 Top Global Pulmonary Arterial Hypertension Treatment Companies Ranked by Revenue
3.3 Global Pulmonary Arterial Hypertension Treatment Revenue by Companies
3.4 Top 3 and Top 5 Pulmonary Arterial Hypertension Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Pulmonary Arterial Hypertension Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Pulmonary Arterial Hypertension Treatment Players in Global Market
3.6.1 List of Global Tier 1 Pulmonary Arterial Hypertension Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Pulmonary Arterial Hypertension Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Pulmonary Arterial Hypertension Treatment Market Size Markets, 2022 & 2029
4.1.2 Vasodilators
4.1.3 Phosphodiesterase 5 (PDE 5) Inhibitors
4.1.4 Endothelin Receptor Antagonists (ERA)
4.1.5 Soluble Guanylate Cyclase (SGC) Stimulator
4.2 By Type – Global Pulmonary Arterial Hypertension Treatment Revenue & Forecasts
4.2.1 By Type – Global Pulmonary Arterial Hypertension Treatment Revenue, 2018-2023
4.2.2 By Type – Global Pulmonary Arterial Hypertension Treatment Revenue, 2024-2029
4.2.3 By Type – Global Pulmonary Arterial Hypertension Treatment Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Pulmonary Arterial Hypertension Treatment Market Size, 2022 & 2029
5.1.2 Hospital Pharmacies
5.1.3 Retail Pharmacies
5.1.4 Online Pharmacies
5.2 By Application – Global Pulmonary Arterial Hypertension Treatment Revenue & Forecasts
5.2.1 By Application – Global Pulmonary Arterial Hypertension Treatment Revenue, 2018-2023
5.2.2 By Application – Global Pulmonary Arterial Hypertension Treatment Revenue, 2024-2029
5.2.3 By Application – Global Pulmonary Arterial Hypertension Treatment Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Pulmonary Arterial Hypertension Treatment Market Size, 2022 & 2029
6.2 By Region – Global Pulmonary Arterial Hypertension Treatment Revenue & Forecasts
6.2.1 By Region – Global Pulmonary Arterial Hypertension Treatment Revenue, 2018-2023
6.2.2 By Region – Global Pulmonary Arterial Hypertension Treatment Revenue, 2024-2029
6.2.3 By Region – Global Pulmonary Arterial Hypertension Treatment Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Pulmonary Arterial Hypertension Treatment Revenue, 2018-2029
6.3.2 US Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.3.3 Canada Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.3.4 Mexico Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Pulmonary Arterial Hypertension Treatment Revenue, 2018-2029
6.4.2 Germany Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.4.3 France Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.4.4 U.K. Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.4.5 Italy Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.4.6 Russia Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.4.7 Nordic Countries Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.4.8 Benelux Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Pulmonary Arterial Hypertension Treatment Revenue, 2018-2029
6.5.2 China Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.5.3 Japan Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.5.4 South Korea Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.5.5 Southeast Asia Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.5.6 India Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Pulmonary Arterial Hypertension Treatment Revenue, 2018-2029
6.6.2 Brazil Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.6.3 Argentina Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Pulmonary Arterial Hypertension Treatment Revenue, 2018-2029
6.7.2 Turkey Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.7.3 Israel Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.7.4 Saudi Arabia Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
6.7.5 UAE Pulmonary Arterial Hypertension Treatment Market Size, 2018-2029
7 Pulmonary Arterial Hypertension Treatment Companies Profiles
7.1 GSK
7.1.1 GSK Company Summary
7.1.2 GSK Business Overview
7.1.3 GSK Pulmonary Arterial Hypertension Treatment Major Product Offerings
7.1.4 GSK Pulmonary Arterial Hypertension Treatment Revenue in Global Market (2018-2023)
7.1.5 GSK Key News & Latest Developments
7.2 Eli Lilly and Company
7.2.1 Eli Lilly and Company Company Summary
7.2.2 Eli Lilly and Company Business Overview
7.2.3 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Major Product Offerings
7.2.4 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Revenue in Global Market (2018-2023)
7.2.5 Eli Lilly and Company Key News & Latest Developments
7.3 Pfizer Inc
7.3.1 Pfizer Inc Company Summary
7.3.2 Pfizer Inc Business Overview
7.3.3 Pfizer Inc Pulmonary Arterial Hypertension Treatment Major Product Offerings
7.3.4 Pfizer Inc Pulmonary Arterial Hypertension Treatment Revenue in Global Market (2018-2023)
7.3.5 Pfizer Inc Key News & Latest Developments
7.4 Actelion Inc
7.4.1 Actelion Inc Company Summary
7.4.2 Actelion Inc Business Overview
7.4.3 Actelion Inc Pulmonary Arterial Hypertension Treatment Major Product Offerings
7.4.4 Actelion Inc Pulmonary Arterial Hypertension Treatment Revenue in Global Market (2018-2023)
7.4.5 Actelion Inc Key News & Latest Developments
7.5 United Therapeutic Corporation
7.5.1 United Therapeutic Corporation Company Summary
7.5.2 United Therapeutic Corporation Business Overview
7.5.3 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Major Product Offerings
7.5.4 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Revenue in Global Market (2018-2023)
7.5.5 United Therapeutic Corporation Key News & Latest Developments
7.6 SteadyMed Ltd
7.6.1 SteadyMed Ltd Company Summary
7.6.2 SteadyMed Ltd Business Overview
7.6.3 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Major Product Offerings
7.6.4 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Revenue in Global Market (2018-2023)
7.6.5 SteadyMed Ltd Key News & Latest Developments
7.7 Gilead Sciences, Inc
7.7.1 Gilead Sciences, Inc Company Summary
7.7.2 Gilead Sciences, Inc Business Overview
7.7.3 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Major Product Offerings
7.7.4 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Revenue in Global Market (2018-2023)
7.7.5 Gilead Sciences, Inc Key News & Latest Developments
7.8 Teva Pharmaceuticals Inc
7.8.1 Teva Pharmaceuticals Inc Company Summary
7.8.2 Teva Pharmaceuticals Inc Business Overview
7.8.3 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Major Product Offerings
7.8.4 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Revenue in Global Market (2018-2023)
7.8.5 Teva Pharmaceuticals Inc Key News & Latest Developments
7.9 Bayer AG
7.9.1 Bayer AG Company Summary
7.9.2 Bayer AG Business Overview
7.9.3 Bayer AG Pulmonary Arterial Hypertension Treatment Major Product Offerings
7.9.4 Bayer AG Pulmonary Arterial Hypertension Treatment Revenue in Global Market (2018-2023)
7.9.5 Bayer AG Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Pulmonary Arterial Hypertension Treatment Market Opportunities & Trends in Global Market
Table 2. Pulmonary Arterial Hypertension Treatment Market Drivers in Global Market
Table 3. Pulmonary Arterial Hypertension Treatment Market Restraints in Global Market
Table 4. Key Players of Pulmonary Arterial Hypertension Treatment in Global Market
Table 5. Top Pulmonary Arterial Hypertension Treatment Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Pulmonary Arterial Hypertension Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Pulmonary Arterial Hypertension Treatment Revenue Share by Companies, 2018-2023
Table 8. Global Companies Pulmonary Arterial Hypertension Treatment Product Type
Table 9. List of Global Tier 1 Pulmonary Arterial Hypertension Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Pulmonary Arterial Hypertension Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Pulmonary Arterial Hypertension Treatment Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Pulmonary Arterial Hypertension Treatment Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Pulmonary Arterial Hypertension Treatment Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Pulmonary Arterial Hypertension Treatment Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Pulmonary Arterial Hypertension Treatment Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Pulmonary Arterial Hypertension Treatment Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2024-2029
Table 30. GSK Company Summary
Table 31. GSK Pulmonary Arterial Hypertension Treatment Product Offerings
Table 32. GSK Pulmonary Arterial Hypertension Treatment Revenue (US$, Mn) & (2018-2023)
Table 33. GSK Key News & Latest Developments
Table 34. Eli Lilly and Company Company Summary
Table 35. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Product Offerings
Table 36. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Revenue (US$, Mn) & (2018-2023)
Table 37. Eli Lilly and Company Key News & Latest Developments
Table 38. Pfizer Inc Company Summary
Table 39. Pfizer Inc Pulmonary Arterial Hypertension Treatment Product Offerings
Table 40. Pfizer Inc Pulmonary Arterial Hypertension Treatment Revenue (US$, Mn) & (2018-2023)
Table 41. Pfizer Inc Key News & Latest Developments
Table 42. Actelion Inc Company Summary
Table 43. Actelion Inc Pulmonary Arterial Hypertension Treatment Product Offerings
Table 44. Actelion Inc Pulmonary Arterial Hypertension Treatment Revenue (US$, Mn) & (2018-2023)
Table 45. Actelion Inc Key News & Latest Developments
Table 46. United Therapeutic Corporation Company Summary
Table 47. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Product Offerings
Table 48. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Revenue (US$, Mn) & (2018-2023)
Table 49. United Therapeutic Corporation Key News & Latest Developments
Table 50. SteadyMed Ltd Company Summary
Table 51. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Product Offerings
Table 52. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Revenue (US$, Mn) & (2018-2023)
Table 53. SteadyMed Ltd Key News & Latest Developments
Table 54. Gilead Sciences, Inc Company Summary
Table 55. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Product Offerings
Table 56. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Revenue (US$, Mn) & (2018-2023)
Table 57. Gilead Sciences, Inc Key News & Latest Developments
Table 58. Teva Pharmaceuticals Inc Company Summary
Table 59. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Product Offerings
Table 60. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Revenue (US$, Mn) & (2018-2023)
Table 61. Teva Pharmaceuticals Inc Key News & Latest Developments
Table 62. Bayer AG Company Summary
Table 63. Bayer AG Pulmonary Arterial Hypertension Treatment Product Offerings
Table 64. Bayer AG Pulmonary Arterial Hypertension Treatment Revenue (US$, Mn) & (2018-2023)
Table 65. Bayer AG Key News & Latest Developments
List of Figures
Figure 1. Pulmonary Arterial Hypertension Treatment Segment by Type in 2022
Figure 2. Pulmonary Arterial Hypertension Treatment Segment by Application in 2022
Figure 3. Global Pulmonary Arterial Hypertension Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Pulmonary Arterial Hypertension Treatment Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Pulmonary Arterial Hypertension Treatment Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Pulmonary Arterial Hypertension Treatment Revenue in 2022
Figure 8. By Type - Global Pulmonary Arterial Hypertension Treatment Revenue Market Share, 2018-2029
Figure 9. By Application - Global Pulmonary Arterial Hypertension Treatment Revenue Market Share, 2018-2029
Figure 10. By Type - Global Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Pulmonary Arterial Hypertension Treatment Revenue Market Share, 2018-2029
Figure 12. By Application - Global Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Pulmonary Arterial Hypertension Treatment Revenue Market Share, 2018-2029
Figure 14. By Region - Global Pulmonary Arterial Hypertension Treatment Revenue Market Share, 2018-2029
Figure 15. By Country - North America Pulmonary Arterial Hypertension Treatment Revenue Market Share, 2018-2029
Figure 16. US Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Pulmonary Arterial Hypertension Treatment Revenue Market Share, 2018-2029
Figure 20. Germany Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 21. France Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Pulmonary Arterial Hypertension Treatment Revenue Market Share, 2018-2029
Figure 28. China Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 32. India Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Pulmonary Arterial Hypertension Treatment Revenue Market Share, 2018-2029
Figure 34. Brazil Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Pulmonary Arterial Hypertension Treatment Revenue Market Share, 2018-2029
Figure 37. Turkey Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Pulmonary Arterial Hypertension Treatment Revenue, (US$, Mn), 2018-2029
Figure 41. GSK Pulmonary Arterial Hypertension Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Pfizer Inc Pulmonary Arterial Hypertension Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Actelion Inc Pulmonary Arterial Hypertension Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Bayer AG Pulmonary Arterial Hypertension Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 肺動脈高血圧症治療の世界市場見通し2023年-2029年(Pulmonary Arterial Hypertension Treatment Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

肺動脈高血圧症治療の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp